Literature DB >> 21987601

Management of Crohn's disease in smokers: is an alternative approach necessary?

Pilar Nos1, Eugeni Domènech.   

Abstract

Inflammatory bowel disease is a chronic condition with a pathogenic background that involves both genetic and environmental factors. Although important progress has been made regarding the former in the last decade, scarce knowledge is available for the latter. In this sense, smoking remains the most important environmental factor in IBD. Active smoking increases the risk of developing Crohn's disease (CD). Moreover, CD patients who start or continue smoking after disease diagnosis are at risk for poorer outcomes such as higher therapeutic requirements and disease-related complications, as compared to those patients who quit smoking or who never smoked. However, the harmful effect of active smoking is not uniform in all patients or in all clinical scenarios. Interventions designed to facilitate smoking cessation may impact the course of the disease. In this article, the available evidence of the deleterious effects of smoking on CD is reviewed in detail, and alternative therapeutic approaches to CD in smokers are proposed.

Entities:  

Keywords:  Complications; Crohn’s disease; Recurrence; Smoking cessation; Therapy; Tobacco

Mesh:

Year:  2011        PMID: 21987601      PMCID: PMC3180011          DOI: 10.3748/wjg.v17.i31.3567

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  66 in total

Review 1.  Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis.

Authors:  Victoria E McGilligan; Julie M W Wallace; Patricia M Heavey; Diana L Ridley; Ian R Rowland
Journal:  Inflamm Bowel Dis       Date:  2007-01       Impact factor: 5.325

Review 2.  Antidepressants for smoking cessation.

Authors:  J R Hughes; L F Stead; T Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 3.  Effect of smoking on inflammatory bowel disease: Is it disease or organ specific?

Authors:  A Karban; R Eliakim
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

4.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

Review 5.  Review article: can post-operative recurrence in Crohn's disease be prevented?

Authors:  M Lémann
Journal:  Aliment Pharmacol Ther       Date:  2006-10       Impact factor: 8.171

6.  Smoking and inflammatory bowel disease: a meta-analysis.

Authors:  Suhal S Mahid; Kyle S Minor; Roberto E Soto; Carlton A Hornung; Susan Galandiuk
Journal:  Mayo Clin Proc       Date:  2006-11       Impact factor: 7.616

7.  The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean area.

Authors:  Maria Concetta Renda; Ambrogio Orlando; Giuseppe Civitavecchia; Valeria Criscuoli; Aurelio Maggio; Filippo Mocciaro; Francesca Rossi; Daniela Scimeca; Irene Modesto; Lorenzo Oliva; Mario Cottone
Journal:  Am J Gastroenterol       Date:  2008-03       Impact factor: 10.864

Review 8.  Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?

Authors:  Sheila A Doggrell
Journal:  Expert Opin Pharmacother       Date:  2007-12       Impact factor: 3.889

Review 9.  Nicotine replacement therapy for smoking cessation.

Authors:  L F Stead; R Perera; C Bullen; D Mant; T Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

10.  The impact of genetic testing for Crohn's disease, risk magnitude and graphical format on motivation to stop smoking: an experimental analogue study.

Authors:  A J Wright; C Takeichi; S C L Whitwell; M Hankins; T M Marteau
Journal:  Clin Genet       Date:  2008-02-05       Impact factor: 4.438

View more
  11 in total

Review 1.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 2.  The intestinal cholinergic anti-inflammatory pathway.

Authors:  Gera Goverse; Michelle Stakenborg; Gianluca Matteoli
Journal:  J Physiol       Date:  2016-05-05       Impact factor: 5.182

Review 3.  Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease?

Authors:  Roberto Bringiotti; Enzo Ierardi; Rosa Lovero; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 4.  Influence of environmental factors in the development of inflammatory bowel diseases.

Authors:  Evangelia Legaki; Maria Gazouli
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 5.  Psychosocial issues in evidence-based guidelines on inflammatory bowel diseases: a review.

Authors:  Winfried Häuser; Gabriele Moser; Petra Klose; Antonina Mikocka-Walus
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 6.  The vagal innervation of the gut and immune homeostasis.

Authors:  Gianluca Matteoli; Guy E Boeckxstaens
Journal:  Gut       Date:  2012-09-29       Impact factor: 23.059

Review 7.  Optimizing post-operative Crohn's disease treatment.

Authors:  Eugeni Domènech; Míriam Mañosa; Triana Lobatón; Eduard Cabré
Journal:  Ann Gastroenterol       Date:  2014

8.  Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans.

Authors:  Luc Biedermann; Jonas Zeitz; Jessica Mwinyi; Eveline Sutter-Minder; Ateequr Rehman; Stephan J Ott; Claudia Steurer-Stey; Anja Frei; Pascal Frei; Michael Scharl; Martin J Loessner; Stephan R Vavricka; Michael Fried; Stefan Schreiber; Markus Schuppler; Gerhard Rogler
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

Review 9.  Management of Crohn Disease: A Review.

Authors:  Kelly Cushing; Peter D R Higgins
Journal:  JAMA       Date:  2021-01-05       Impact factor: 157.335

Review 10.  Bacterial microbiome of lungs in COPD.

Authors:  Marc A Sze; James C Hogg; Don D Sin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.